Half Year Accounts and Chairman Letter
Filed with ASX · · 23 pages · English
In the deck
Story so far
Earlier from Noxopharm
- FDA grants IND approval to Veyonda
- Noxopharm Alliance With GenesisCare
- LuPIN Trial Interim Results Indicate Striking Survival Benefit
- $8.1M Financing & Re-Set of Capital Structure
- Noxopharm Dec 2019 Appendix 4C
Later from Noxopharm
- LuPIN Prostate Cancer Trial Fully Recruited
- Veyonda Awarded First Allowed Patent Application
- Noxopharm Investigating Potential COVID-19 Treatment
- Approval to be sought for COVID-19 Clinical Study in U.S.
- Pipeline Expands With Potential New Brain Cancer Treatment
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm